Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands

Annals of Surgical Oncology

Volumn 24, Issue 7, 2017, Pages 1761-1769

  Brenkman, H J F ^a   Visser, E ^a   van Rossum, P S N ^a   Siesling, S ^b,c   van Hillegersberg, R ^a   Ruurda, J P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Netherlands Comprehensive Cancer Organisation ^*  (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOSCOPIC ULTRASONOGRAPHY; FEMALE; GASTRECTOMY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOADJUVANT CHEMOTHERAPY; NEOADJUVANT THERAPY; NETHERLANDS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; STOMACH CANCER; TOTAL STOMACH RESECTION; ADENOCARCINOMA; FOLLOW UP; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH TUMOR; SURVIVAL RATE; TIME TO TREATMENT;

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NETHERLANDS; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TIME-TO-TREATMENT;

EID: 85016090057     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-017-5820-8     Document Type: Article

References (26)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Vereniging Integrale Kankercentra. Diagnostiek, behandeling en follow-up van het maagcarcinoom. 2009. http://www.oncoline.nl/uploaded/docs/Maagcarcinoom/Richtlijn%20maagcarcinoom.pdf.
3. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.
4. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.
5. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.
6. DUCA Jaarrapportage, 2014. Available at: http://www.clinicalaudit.nl/jaarrapportage/2014/duca.html.
7. Visser MR, van Lanschot JJ, van der Velden J, Kloek JJ, Gouma DJ, Sprangers MA. Quality of life in newly diagnosed cancer patients waiting for surgery is seriously impaired. J Surg Oncol. 2006;93:571–7.
8. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112(suppl 1):S92–107.
9. Advies inzake wachttijdnormen in de kankerzorg. http://www.oncoline.nl/uploaded/docs/Draaiboek/Normatieve %20wachttijden.pdf.
10. Normeringsrapport SONCOS. February 6, 2015. http://www.soncos.org/.
11. Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol. 2012;23:2731–7.
12. Griffin SM. Gastric cancer in the East: same disease, different patient. Br J Surg. 2005;92:1055–6.
13. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.
14. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
15. Visser E, Leeftink AG, van Rossum PS, Siesling S, van Hillegersberg R, Ruurda JP. Waiting time from diagnosis to treatment has no impact on survival in patients with esophageal cancer. Ann Surg Oncol. 2016;23:2679–89.
16. Grotenhuis BA, van Hagen P, Wijnhoven BP, Spaander MC, Tilanus HW, van Lanschot JJ. Delay in diagnostic workup and treatment of esophageal cancer. J Gastrointest Surg. 2010;14:476–83.
17. McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol. 2012;30:4493–500.
18. Elit LM, O’Leary EM, Pond GR, Seow HY. Impact of wait times on survival for women with uterine cancer. J Clin Oncol. 2014;32:27–33.
19. van Harten MC, Hoebers FJ, Kross KW, van Werkhoven ED, van den Brekel MW, van Dijk BA. Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol. 2015;51:272–8.
20. Eshuis WJ, van der Gaag NA, Rauws EA, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. Ann Surg. 2010;252:840–9.
21. Murchie P, Raja EA, Brewster DH, et al. Time from first presentation in primary care to treatment of symptomatic colorectal cancer: effect on disease stage and survival. Br J Cancer. 2014;111:461–9.
22. Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A. Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer. 2007;43:2467–78.
23. Witzig R, Schonberger B, Fink U, et al. Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy. 2006;38:1122–6.
24. Seevaratnam R, Cardoso R, McGregor C, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2012;15(suppl 1):S3–18.
25. Correia MI, Waitzberg DL. The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. Clin Nutr. 2003;22:235–9.
26. Dikken JL, van Sandick JW, Allum WH, et al. Differences in outcomes of oesophageal and gastric cancer surgery across Europe. Br J Surg. 2013;100:83–94.